<DOC>
	<DOCNO>NCT02978690</DOCNO>
	<brief_summary>This phase I , open label , single group study perform assess safety , tolerability , Pharmacokinetics ( PK ) , Pharmacogenomics ( PGx ) efficacy single dose BI 655130 adult patient active Generalized Pustular Psoriasis ( GPP ) .</brief_summary>
	<brief_title>BI655130 Single Dose Generalized Pustular Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Inclusion criterion : Male female patient , age 18 75 year screen , A know documented history Generalized Pustular Psoriasis Presenting flare Generalized Pustular Psoriasis A Generalized Pustular Psoriasis Physician Global Assessment score least moderate severity , Generalized Pustular Psoriasis patient receive maintenance treatment retinoids and/or methotrexate least 4 week Generalized Pustular Psoriasis patient receive maintenance therapy , screening , Signed date write informed consent prior admission study , Women childbearing potential must ready able use highly effective method birth control per ICH M3 ( R2 ) result low failure rate le 1 % per year use consistently correctly . A list contraception method meet criterion provide patient information . Male patient must ready able use condom . Further inclusion criterion apply Exclusion criterion : Women pregnant , nursing , plan become pregnant trial . Immediate lifethreatening flare Generalized Pustular Psoriasis require intensive care treatment , accord , judgement investigator . Lifethreatening complication mainly include , limited , cardiovascular/cytokine driven shock , pulmonary distress , Identified , ongoing serious/severe infection , Acute generalize exanthematous pustulosis ( AEGP ) Patient 's clinical presentation consider due differential diagnosis toxic epidermal necrosis StevensJohnson syndrome , Currently involve intend participate another investigational study course trial , Previous enrolment trial Use restrict medication , drug consider likely interfere safe conduct study Background therapy ciclosporin within last 30 day precede second screen visit , Severe , progressive , uncontrolled renal , hepatic , haematological , endocrine , pulmonary , cardiac , neurologic , cerebral , psychiatric disease , sign symptom thereof , judge investigator . Known chronic relevant acute infection include active tuberculosis , HIV viral hepatitis ; QuantiFERONÂ® tuberculosis test perform screening . If result positive , patient may participate study work ( accord local practice/guidelines ) establish conclusively patient evidence active tuberculosis . If presence latent tuberculosis establish , treatment initiate maintain accord local country guideline . Patient transplant organ ( exception corneal transplant &gt; 12 week prior screen ) ever receive stem cell therapy ( e.g. , Prochymal ) . Known history lymphoproliferative disease , include lymphoma , sign symptom suggestive possible lymphoproliferative disease , lymphadenopathy and/or splenomegaly . Any document active suspected malignancy history malignancy within 5 year prior second screen visit , except appropriately treat basal squamous cell carcinoma skin situ carcinoma uterine cervix . Evidence current previous disease , medical condition ( include chronic alcohol drug abuse ) Generalized Pustular Psoriasis , surgical procedure ( i.e. , organ transplant ) , medical examination finding ( include vital sign electrocardiogram ) , laboratory value second screen visit outside reference range , opinion investigator , clinically significant would make study participant unreliable adhere protocol complete trial , compromise safety patient , compromise quality data , Further exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>